Duke Comp Cancer Inst. Core Support Grant

最近重组的杜克综合癌症研究所(DCCI)被指控为 杜克大学在癌症方面的所有活动，未来有必要监督杜克大学的所有癌症业务。AS 作为最大的生物医学研究机构之一的矩阵中心，DCCI一直在 在国家癌症研究所(NCI)的支持下，通过利用杜克大学的基础研究 优势与显著的临床肿瘤学研究卓越，这是通过治疗5581个新的 每年癌症患者，每年招募1000多名患者参加治疗临床试验，并增强 由于存在国家肿瘤学研究资源，如两个数据和统计中心 NCI资助的合作团体。DCCI的成员总数为285人，其中成员有 自2004年以来，癌症研究的重点日益突出，NCI的资助额不断增加。总计 为计划成员提供的资金为331,617,013美元，其中269,525,804美元来自同行审查来源。一个 《癌症焦点》由NCI、美国癌症协会或 国防部。从2004年到2008年，项目成员在同行评议中发表了6941篇论文 在PubMed上被引用的期刊。在这些出版物中，10%是方案内协作的结果， 19%的原因是方案间的协作。在此竞争性续订申请中，我们请求支持 我们在由17个共享资源支持的11个研究项目中的成员资格。DCCI成员 重大的科学进步包括：开发创新的基因组测试来预测哪种癌症 患者会对特定的化疗有反应，并对癌症中的关键信号通路有基本的了解 和发育生物学。DCCI负责监督杜克大学所有与癌症有关的慈善活动，这些基金 已用于支持招募新成员、创新试点项目、支持多学科 研究，以及新的实验室和行政空间。此申请要求持续支持 DCC阐明了推动DCCI充分利用 杜克大学和其他地方在生物医学研究方面的巨大进步，以改善和延长癌症的生命 癌症患者和有癌症风险的患者，并向社会提供这些服务。

The recently reorganized Duke Comprehensive Cancer Institute (DCCI) is charged to serve as the center of all Duke activities in cancer, with an imperative to oversee all of the Duke cancer operations in the future. As a matrix center in one of the largest biomedical research institutes, the DCCI has been continuously supported by the National Cancer Institute (NCI) for over 36 years, by leveraging Duke's basic research strengths with significant clinical oncology research excellence which is enabled by treating 5,581 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. Total membership in the DCCI is 285 members, with members having an increasingly prominent focus in cancer research and increased amount of NCI funding since 2004. Total funding for program members is $331,617,013, of which $269,525,804 is from peer-reviewed sources. A cancer focus is illustrated by $77,785,582 or 23.5% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004-2008, program members published 6,941 papers in peer-reviewed journals cited in PubMed. Of these publications, 10% are the result of intra-programmatic collaborations and 19% due to inter-programmatic collaborations. In this competitive renewal application, we request support our membership in 11 Research Programs supported by 17 Shared Resources. DCCI members made significant scientific advances including: the development of innovative genomic tests to predict which cancer patients would respond to specific chemotherapy, and basic insight into critical signaling pathways in cancer and developmental biology. The DCCI oversees all cancer related philanthropy at Duke, and these funds have been used to support recruitment of new members, innovative pilot projects, support of multidisciplinary research, and new laboratory and administrative space. This application for ongoing support of the DCC articulates the principles, goals and strategies for propelling the DCCI to fully leverage the enormous advances in biomedical research at Duke and beyond, to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.